Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06320262
Other study ID # NRC/TDF/01/F
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2024
Est. completion date April 2025

Study information

Verified date March 2024
Source Cairo University
Contact Rasmia M Elgohary, A. Prof.
Phone 01111370118
Email rasmiaelgohary@kasralainy.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fibromyalgia has become one of the most prevalent chronic pain conditions that impair quality of life. Wet cupping has gained increasing popularity in treating painful conditions. This study aims to investigate the effectiveness of wet cupping therapy combined with home-based exercise compared to home-based exercise alone in improving patients diagnosed with primary fibromyalgia syndrome.


Description:

Background: The fibromyalgia (FM) syndrome is characterized by widespread chronic pain accompanied by fatigue, cognitive disturbances, sleep disorders, and pronounced somatic and/or psychological distress that impair the quality of life. So far there is no definitive treatment for FM. All available guidelines agreed on the first-line role of non-pharmacological therapies over pharmacological agents. Cupping therapy (Hijama in Arabic) is an ancient medical art that has been used primarily in the treatment of several painful conditions and has regained popularity in modern medicine. Purpose: Our study aims to investigate the efficacy of wet cupping therapy in treating patients diagnosed with primary fibromyalgia. Method: the study will include 50 female patients who had been diagnosed with fibromyalgia syndrome (FMS) according to the American College of Rheumatology (ACR) criteria and had symptoms not exceeding two years. The eligible patients will further undergo Brain magnetic resonance spectroscopy and clinical assessment including evaluation of the following 1. Widespread pain index (WPI) and pain intensity using a Visual Analog Scale (VAS), 2. Total impact of FM as measured by the validated Arabic version of the Revised Fibromyalgia Impact Questionnaire (FIQR). 3. Evaluation of sleep disturbance using the Jenkins sleep score 4. Evaluation of fatigue using a horizontal line (VAS) anchored by "0=No fatigue " and "100=Worst imaginable fatigue 5. Evaluation of Depression and anxiety using the validated Arabic version of Hospital Anxiety and Depression Scale (HADS) 6. Cognitive function assessment using the Montreal Cognitive Assessment (MoCA) 7. Complete blood count Randomization: All eligible patients will receive instructions on a home-based graded exercise program, then the patients will randomly be assigned into two groups 1. Control group: will be kept on home-based exercise alone 2. Intervention group: They will receive wet cupping therapy in addition to home-based exercise. Follow-up assessments: at week 12 after initiating the therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date April 2025
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Adult patients aged 18-55 years. - Female individuals to avoid the gender confounding factor. - Clinical diagnosis of primary fibromyalgia according to the 2016 American College of Rheumatology (ACR) updated diagnostic criteria. - The duration of the disease does not exceed two years. - Moderate pain intensity of = 45 mm or higher on a visual analog scale (VAS). - No use of skeletal muscle relaxants, antidepressants, antiepileptic drugs, corticosteroids, benzodiazepines, and tramadol within a year before the screening visit. Exclusion Criteria: - Underlying rheumatic, malignant, metabolic, hematological, or neurological disorders. - Patients with bleeding disorders or receiving anticoagulants. - Previous use, within a year, or current use of skeletal muscle relaxants, antidepressants, antiepileptic drugs, corticosteroids, benzodiazepines, or tramadol - Patients with BMI = 18 or = 35. - Pregnant or lactating women. - Patients with severe anemia.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Wet cupping therapy (WCT)
Type of cupping: Triple-stage wet cupping therapy (Hijama) will be used; sucking, scarification, sucking. Cupping points will include one cup on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra (Alkahil area); two points in the inter-scapular region 3cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra, two points at inferior angle of the scapula (3cm lateral to lower border of the spinous process of the 7th thoracic vertebra, 2 points at lumbar regions, in addition to the most painful areas. After the procedure: Areas of cupping will be covered using sterile gauze. All used tools and materials will be collected in red bags to ensure proper waste disposal. Sharp objects will be disposed of in the sharps disposal box. Telephone follow-up with all patients 48 hours after cupping will be done.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Rasmia Elgohary

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline brain MRS Voxel placement will be applied to study the following brain centers both thalami, insular regions, amygdalae, hippocampi, superior frontal gyri, and anterior cingulate gyri to determine the concentration of brain neurometabolites Nacetylaspartate (NAA), choline (Cho), and creatine (Cr) and their ratios. At the time of inclusion and at week 12
Secondary Change from baseline Visual Analog Scale (VAS) Evaluation of pain using a horizontal line (VAS) anchored by "0=No pain" and "100=Worst pain At the time of inclusion and at week 12
Secondary Change from baseline in the individual components of the Fibromyalgia Impact Questionnaire Revised (FIQR) the FIQR is a commonly used instrument in the evaluation of FM patients. It contains 21 questions in 3 domains: function (9 questions), overall impact (2 questions), and symptoms (10 questions), a validated Arabic version will be used. At the time of inclusion and at week 12
Secondary Change from the baseline sleep disturbance using the Jenkins sleep score (JSS) Jenkins sleep score (JSS) is a 4-item questionnaire to follow common sleep problems.
The frequency of sleep problems in the last month is evaluated using four items: difficulty falling asleep, waking up at night, difficulty staying asleep, and non-restorative sleep (ie, waking up after the usual amount of sleep feeling tired and worn out).
Each item is rated on a Likert-like scale from 0 to 5, where 0 is 'never', 1 is '1-3 days', 2 is 'about 1 night/week', 3 is '2-4 nights/week', 4 is '5-6 nights/week' and 5 is 'almost every night'.
The total score is a simple sum of all four items' scores and ranges from 0 (no sleep problems) to 20 (most sleep problems). The score of 11 is a cut-off-a score <12 is defined as little sleep disturbances and a score >11 is understood as a high frequency of sleep disturbances.
At the time of inclusion and at week 12
Secondary Change from baseline Fatigue- VAS. Evaluation of fatigue using a horizontal line (VAS) anchored by "0=No fatigue " and "100=Worst imaginable fatigue At the time of inclusion and at week 12
Secondary Change from baseline of Hospital Anxiety and Depression Scale (HADS) The Hospital Anxiety and Depression Scale (HADS) evaluates depression and anxiety, it produces two scales, one for anxiety (HADS-A) and one for depression (HADS-D). Scores greater than or equal to 11 on either scale indicate a definitive case. A validated Arabic version will be used. At the time of inclusion and at week 12
Secondary Change from baseline of the Montreal Cognitive Assessment (MoCA) The Montreal Cognitive Assessment score examines seven domains (aspects) of cognitive function (executive/visuospatial function, naming, attention, language, abstraction, recall, and orientation). The maximum score is 30. the score is interpreted as follows; Normal cognition: 26-30 points, Mild cognitive impairment: 18-25 points, Moderate cognitive impairment: 10-17 points, Severe cognitive impairment: Under 10 points. At the time of inclusion and at week 12
Secondary Change from baseline of the Widespread pain index (WPI) The widespread pain index evaluates the number of painful areas out of a total of 19 areas, and the number is expected to decrease as the patient improves and vice versa. At the time of inclusion and at week 12
Secondary Change from baseline hemoglobin hemoglobin will be assessed in the complete blood count At the time of inclusion and at week 12
Secondary patient compliance on exercise as instructed All patients will be asked to complete activity diaries daily to assess adherence. Exercise adherence is considered when the patient can participate in 80% of the prescribed exercise sessions. This diary will be reviewed at weeks 4, 8 and 12
See also
  Status Clinical Trial Phase
Recruiting NCT05243134 - The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
Completed NCT02486874 - Clinical Evaluation of PoreSkin Phase 1
Active, not recruiting NCT04592640 - Stem Cells for Uremic Calciphylaxis Patients N/A
Recruiting NCT04599686 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer N/A
Recruiting NCT03351842 - Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% Phase 2
Completed NCT03439930 - The Effect of Balance Training on Neuromuscular Control in Subjects With CAI N/A
Completed NCT02782442 - Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) N/A
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Recruiting NCT02971982 - PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Phase 1/Phase 2
Completed NCT02820272 - Water for Reducing Pain in Negative Pressure Wound Therapy Phase 2
Completed NCT00984958 - Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure N/A
Completed NCT00575224 - Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 Phase 4
Completed NCT00164307 - Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships Phase 1/Phase 2
Completed NCT00164528 - Intervening With Children/Adolescents With FAS/ARND Phase 1/Phase 2
Recruiting NCT04603586 - Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses N/A
Recruiting NCT03375424 - Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany N/A
Not yet recruiting NCT04062370 - Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion Phase 4
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Completed NCT04661228 - Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
Recruiting NCT03365141 - Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo N/A